Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined...
Reexamination Certificate
2011-01-18
2011-01-18
Kim, Taeyoon (Department: 1651)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
C424S582000, C424S583000
Reexamination Certificate
active
07871646
ABSTRACT:
A method of preparing an amniotic membrane extract including the steps of obtaining a healthy amniotic membrane from a pregnant mammal, such as a pig, cow, horse or human, homogenizing the membrane to obtain a homogenate solution, freezing the homogenate solution, and lyophilizing the frozen homogenate solution to dryness is disclosed. Preferably, the lyophilized homogenate is pulverized to a powder. The lyophilized homogenate is then reconstituted before use, e.g., in a liquid, such as a balanced salt solution or fresh amniotic fluid, or in another substance, such a gel, an ointment, a cream or a soap, depending on the intended use. Also disclosed is a pharmaceutical composition prepared according to the method of the invention, for prophylaxis and/or treatment of a disease or condition, especially of the eye or the skin. Exemplary pharmaceutically acceptable carriers for the composition of the invention include an ophthalmic solution for eye drops, a gel, an ointment, an emulsion, a cream, a powder and a spray.
REFERENCES:
patent: 5002071 (1991-03-01), Harrell
patent: 5932205 (1999-08-01), Wang et al.
patent: 6117857 (2000-09-01), Carlsson et al.
patent: 6143315 (2000-11-01), Wang et al.
patent: 6326019 (2001-12-01), Tseng
patent: 2110531 (1983-06-01), None
patent: 2001 100 588 (2001-11-01), None
patent: 2001 098716 (2001-11-01), None
patent: 2001 100588 (2001-11-01), None
Na et al. 1999. Analysis of Human Amniotic Membrane Components as Proteinase Inhibitors for Development of Therapeutic Agent for Recalcitrant Keratitis. Trophoblast Research 13:453-466.
Snowman. 1988. Lyophilization: Freeze-Drying A Downstream Process. Downstream Processes: Equipment and Techniques, Alan R. Liss, Inc. p. 1-2.
Ti et al. 2002. Factors Affecting Outcome Following Transplantation of Ex vivo Expanded Limbal Epithelium on Amniotic Membrane for Total Limbal Deficiency in Rabbits. Investigative Ophthalmology & Visual Science, Aug. 2002, vol. 43, No. 8. p. 2584-2592.
Stedman's Medical Dictionary 27th Edition. 2009. Definition for the term ‘extract’. p. 1.
Orlacchio, A., et al.; “beta-N-Acetyl-d-glucosaminidase isoenzymes from human amnionic membranes”; Clinica Chimica ACTA, Elsevier BV Amsterdam, NL; (1986); 159(3): 279-289.
Database WPI Week 200230; Thomson Scientific, London, GB; AN 2002-251929; XP002528367 & KR 2001 098 716 (Bioland Ltd.) (2001) (abstract).
Database WPI Week 199713; Thomson Scientific, London, GB; AN 1997-143797; XP002528368 & RU 2 063 761 C1 (Pilipenko Yu G) (1996) (abstract).
Kim Taeyoon
Repsco LLP
Weingarten Schurgin, Gagnebin & Lebovici LLP
LandOfFree
Use of a human amniotic membrane composition for prophylaxis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a human amniotic membrane composition for prophylaxis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a human amniotic membrane composition for prophylaxis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702581